Belite Bio Presented Interim Results Of LBS-008 Phase 1b/2 Study In Adolescent STGD1 At ARVO Annual Meeting 2022
Belite Bio Presented Interim Results Of LBS-008 Phase 1b/2 Study In Adolescent STGD1 At ARVO Annual Meeting 2022
LBS-008 (aka Tinlarebant) showed an acceptable safety profile in adolescent Stargardt disease (STGD1) subjects
A trend for stabilized or improved visual acuity was observed
Observed adverse events were anticipated based on the mechanism of LBS-008 action
STGD1 subjects from the Phase 1b study are now participating in the 2-year, Phase 2 extension
LBS-008 (aka Tinlarebant) showed an acceptable safety profile in adolescent Stargardt disease (STGD1) subjects
A trend for stabilized or improved visual acuity was observed
Observed adverse events were anticipated based on the mechanism of LBS-008 action
STGD1 subjects from the Phase 1b study are now participating in the 2-year, Phase 2 extension
LBS-008(又名替拉贝坦)在青少年Stargardt病(STGD1)受试者中显示出可接受的安全性
观察到视力稳定或提高的趋势
根据LBS-008的作用机制预测观察到的不良事件
来自1b期研究的STGD1受试者现在正在参与为期2年的2期延期
译文内容由第三方软件翻译。
风险及免责提示
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用浏览器的分享功能，分享给你的好友吧